Cost-effectiveness of grass allergen tablet (GRAZAX®) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - A Northern European perspective

Clinical and Experimental Allergy

Volumn 37, Issue 5, 2007, Pages 772-779

  Bachert, C ^a   Vestenbaek U ^b   Christensen, J ^b   Griffiths, U K ^c   Poulsen, P B ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ALK ABELLÓ   (Denmark)

^c MUUSMANN Research and Consulting   (Denmark)

Author keywords

Cost effectiveness; Costs; Grass allergen tablet; Grass pollen induced rhinoconjunctivitis; QALY; Symptomatic medication; Tablet based immunotherapy

Indexed keywords

BUDESONIDE; FLUTICASONE; GRASS POLLEN ALLERGEN; GRAZAX; LORATADINE; PLACEBO; POLLEN ANTIGEN; PREDNISONE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ASTHMA; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SPECIFICITY; DRUG UTILIZATION; EUROPE; FEMALE; GRASS; HOME CARE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; POLLEN ALLERGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; STATISTICAL SIGNIFICANCE; TABLET; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DRUG COSTS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHLEUM; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; TABLETS;

EID: 34247488344     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02706.x     Document Type: Article

References (33)

1. Bousquet J, van Cauwenberge P, Khaltaev N, Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl. 5): S147 334.
2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004 24: 758 64.
3. Kjøller M, Rasmussen N. The health and morbidity survey 2000 - and the development since 1987. Copenhagen: Statens Institut for Folkesundhed, 2002 (in Danish).
4. Royal College of Physicians. Allergy: the unmet need, A blueprint for better patient care, June 2003.
5. Linneberg A, Nielsen NH, Frølund L, Madsen F, Dirksen A, Jørgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002 57: 1048 52.
6. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998 101: 352 6.
7. Grossman J. One airway, one disease. Chest 1997 111: 6 11.
8. EFA (European Federation of Allergy and Airway Diseases Patients Association). Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report (2005) ().
9. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of allergen specific immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991 302: 265 9.
10. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen allergen specific immunotherapy. Efficacy and safety during a 4-year follow-up study. Allergy 1995 50: 405 13.
11. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen allergen specific immunotherapy. N Engl J Med 1999 34: 468 75.
12. Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002 109: 251 6.
13. Bousquet J, Lockey R, Malling HJ et al. Allergen allergen specific immunotherapy: therapeutic vaccines for allergic diseases allergy, World Health Organization and American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 81: 401 5.
14. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006 61 (Suppl. 82): 1 20.
15. Passalacqua G, Guerra L, Pasquali M, Canonica GW. Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets 2006 5: 43 51.
16. Adriano R, Berto P, Traci D, Incorvaia C, Frati F. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006 27: 159 63.
17. Pedersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madrid) 2005 33: 296 302.
18. Drummond M, Dubois D, Garattini L et al. Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value in Health 1999 2: 323 32.
19. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 118: 434 40.
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd Edn. Oxford: Oxford Medical Publications, Oxford University Press, 2005.
21. Valovirta E, Jacobsen L, Niggemann B et al. A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study. J Allergy Clin Immunol 2006 117: 721.
22. Petersen KD. Allergibehandling. En samfundsøkonomisk analyse i Århus Amt (Allergy treatment. An economic analysis in Århus County, Denmark). MPH thesis. Master of Public Health, Det Sundhedsvidenskabelige Fakultet, Århus University, 2003.
23. Heyse JF, Cook JR, Carides GW. Statistical considerations in analysing health care resource utilization and cost data, chapter 9. In: Drummond M, McGuire A, eds. Economic evaluation in health care. Merging theory with practice. Oxford: Oxford University Press, 2001 215 25.
24. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000 17: 13 35.
25. Brooks R. EuroQol: the current state of play. Health Policy 1996 37: 53 72.
26. Sculpher M. The use of quality-adjusted life-years in cost-effectiveness studies. Allergy 2006 61: 527 30.
27. National Institute of Clinical Excellence. Guide to the Methods of Technology Appraisal, NHS, London, April 2004.
28. Conference Report. Scottish Medicines Consortium Completes Four Year's Work. IMS Health, PHARMA Pricing & Reimbursement 2006; 10 (1).
29. Mosbech H, Østerballe O. Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988 43: 523 9.
30. Niggemann B, Jacobsen L, The PAT Investigator Group. et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006 61: 855 9.
31. Bachert C, Bousquet J, The XPERT Study Group. et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004 114: 838 44.
32. Lamb CE, Ratner PH, Johnson CE et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006 22: 1203 10.
33. Frew AJ, Powell RJ, Corrigan CJ, Durham SR on behalf of the UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 117: 319 25.